FDA to study TV drug ad imagery

Picture this: An FDA type is reclining in his Barcalounger, watching a few direct-to-consumer ads. Homework. Between bites of popcorn, the FDAer notices something strange. The rolling video in these ads shows healthy, smiling, carefree people--you can almost hear Snow White singing in the background. Almost. Because what you hear instead is a monotone voice reciting a litany of terrible side effects. Anxiety and sleeplessness, weight gain, blood clots that can be fatal, and so on.

What's a diligent agency to do, then? Mount a study. The FDA intends to show a selection of drug ads to 1,000 people over the age of 40, and then ask questions about the subjects' impression of the drug. Are any verbal warnings penetrating the fairy-tale fog induced by those happy-go-lucky images? We'll see.

- read the Wall Street Journal's take on this (sub. req.)

Related Articles:
Study: DTC ad spending on the rise. Report
Does the FDA do enough to regulate drug ads? Report
GAO: Improvements Needed in FDA's oversight of DTC ads. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?